Cargando…
An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
Pyroglutamate amyloid beta3–42 (pGlu-Abeta3–42), a highly amyloidogenic and neurotoxic form of Abeta, is N-terminally truncated to form a pyroglutamate and has recently been proposed as a key target for immunotherapy. Optimized ACI-24, a vaccine in development for the treatment and prevention of Alz...
Autores principales: | Vukicevic, M., Fiorini, E., Siegert, S., Carpintero, R., Rincon-Restrepo, M., Lopez-Deber, P., Piot, N., Ayer, M., Rentero, I., Babolin, C., Bravo-Veyrat, S., Giriens, V., Morici, C., Beuzelin, M., Gesbert, A., Rivot, S., Depretti, S., Donati, P., Streffer, J., Pfeifer, A., Kosco-Vilbois, M. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037369/ https://www.ncbi.nlm.nih.gov/pubmed/35479516 http://dx.doi.org/10.1093/braincomms/fcac022 |
Ejemplares similares
-
Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020) -
Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018) -
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013) -
Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013) -
Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome
por: De Kimpe, Line, et al.
Publicado: (2012)